Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06453590 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06453590 · ClinicalTrials.gov record · last posted 2026-08-20

Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents

StatusActive, Not Recruiting
PhaseNot applicable
Started2020-02-04
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this randomized controlled trial is to compare uncovered, partially covered, and fully covered self-expandable metal stents (SEMS) in the palliative treatment of distal malignant biliary obstruction in a Swedish multicenter study. The main questions it aims to answer is: Is the stent patency rate different depending of stent type? Is the stent patency time different depending of stent type? Is the patient survival different between the groups? Which complications are seen, and do they differ between the groups? Are there different mechanisms behind the stent failure depending on stent type? Patients will at ERCP, with a guidewire passed through the stenosis in the bile duct, be allocated to either uncovered, partially covered, and fully covered (SEMS). Totally, 450 patients will be recruited, 150 in each study arm, according to the power analysis. Patients will be followed in a monthly surveillance by a study nurse up to 12 months after stent insertion. Endpoints are: alive after 12 months with a patent stent, death with a patent stent, stent dysfunction with a subsequent intervention i.e. repeated ERCP or PTC = "objective stent failure", stent dysfunction, jaundice or cholangitis, but not intervention has been undertaken due to a poor condition of the patient, "clinical stent failure", the patient has undergone curative surgery or a bilio-enteric by-pass (a gastro-enteroanastomosis or a duodenal stent is not a reason for exclusion), the patient refuses further follow-up.

Protocol amendment history 2 changes detected by DataLookout

2026-08-21
critical
Primary completion pushed: 2026-01-15 → 2027-01-15
2026-08-21
minor
Completion pushed: 2026-01-15 → 2027-02-15
Trial Details
NCT Number NCT06453590
Lead Sponsor Region Stockholm
Conditions Pancreatic Cancer Non-resectable, Bile Duct Cancer, Papillary Carcinoma, Duodenal Cancer
Enrollment 450 participants
Start Date 2020-02-04
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-20